Alemtuzumab pretreatment and tacrolimus monotherapy in living-donor liver and kidney transplantation

Henkie P. Tan, Ron Shapiro, Kusum Tom, Ngoc Thai, Wallis Marsh, Amit Basu, Amadeo Marcos

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

We previously described the use of alemtuzumab as a pretreatment agent in 207 living-donor renal transplants, a trial that represented the largest series to date of live-donor renal and liver transplant recipients undergoing alemtuzumob pretreatment, and confirmed the short-term safety, efficacy and cost-effectiveness of this approach. This paper examines the use of the immunosuppressive combination of alemtuzumab and tacrolimus monotherapy in 47 patients with right-lobe adult living-donor liver transplantation.

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume7
Issue number2
DOIs
StatePublished - Apr 2007
Externally publishedYes

Keywords

  • Campath
  • Complication
  • Delayed graft function
  • Economics
  • Infection
  • Laparoscopy
  • Prograf
  • Right-lobe donor hepatectomy
  • Steroid free

Fingerprint

Dive into the research topics of 'Alemtuzumab pretreatment and tacrolimus monotherapy in living-donor liver and kidney transplantation'. Together they form a unique fingerprint.

Cite this